Parameter
| Biomarker | BTK mutant (C481S) | Full name | Bruton's tyrosine kinase mutant (C481S) | Molecular Type | Protein (mutant) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prediction of treatment response and drug resistance | ||
| Disease | NHL | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Tissues, cell lines (gene sequencing, in vitro experiments) | ||
| Pathobiological Mechanisms | Mutations lead to resistance to BTK inhibitors, guiding the selection of next-generation inhibitors | ||||
| Clinical Availability Status | Clinical validation phase: validation in relapsed/refractory patients, with sensitivity of detection requiring optimization, clinical drug resistance screening. | ||||
| Notes and Dynamics | Developing ctDNA liquid biopsy to construct mutation profiles for drug resistance assessment. | ||||